Hangzhou Aidecheng

Hangzhou Aidecheng Pharmaceutical Technology is a China-based biotechnology company specializing in the discovery and development of next-generation small molecule therapeutics. The company leverages its proprietary targeted protein degradation (TPD) platform to design bifunctional molecules, such as PROTACs, that facilitate the degradation of disease-causing proteins. Aidecheng's research primarily focuses on high-value targets in oncology and immunology where traditional inhibitors have shown limitations. Its lead programs include degraders targeting Bruton's tyrosine kinase (BTK) and the Estrogen Receptor (ER), aimed at treating various cancers and autoimmune disorders. By utilizing the cell's natural protein disposal system, Aidecheng aims to provide more effective treatments for patients with drug-resistant conditions. The company is headquartered in the Hangzhou High-tech Zone and continues to expand its pipeline of innovative degraders.